What is the difference between ALIROCUMAB and PITAVASTATIN?

ALIROCUMAB is a PCSK9 Inhibitor and PITAVASTATIN is a Other. They reach a similar treatment goal through different pharmacological mechanisms, which is why one may be tolerated by a patient who could not tolerate the other.

Is Praluent the same as Pitavastatin Calcium?

No. Praluent (ALIROCUMAB) and Pitavastatin Calcium (PITAVASTATIN) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, ALIROCUMAB or PITAVASTATIN?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from ALIROCUMAB to PITAVASTATIN?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

ALIROCUMAB vs PITAVASTATIN

Compare ALIROCUMAB (Praluent) and PITAVASTATIN (Pitavastatin Calcium) — clinical data, side effects, and patient experiences.

ALIROCUMAB

Praluent · PCSK9 Inhibitor

How it works

12.1 Mechanism of Action Alirocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein (...

Approved for

1 INDICATIONS AND USAGE PRALUENT ® is indicated: To reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death

myocardial infarction

stroke

myocardial infarction

SubcutaneousTablet

PITAVASTATIN

Pitavastatin Calcium · Other

How it works

12.1 Mechanism of Action Pitavastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonat...

Approved for

See full prescribing information

OralTablet

Quick Comparison

ALIROCUMABPITAVASTATIN

Drug Class

PCSK9 Inhibitor

Other

Route

Subcutaneous

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ALIROCUMAB

Muscle Pain

>10%

Injection Site Pain

1-10%

Joint Pain

1-10%

Fatigue

1-10%

Limb Pain

1-10%

Diarrhea

1-10%

Headache

1-10%

Cough

0.1-1%

PITAVASTATIN

Muscle Pain

>10%

Diarrhea

1-10%

Fatigue

1-10%

Nausea

1-10%

Headache

1-10%

Joint Pain

1-10%

Dizziness

1-10%

Shortness of Breath

1-10%

FDA Warnings

ALIROCUMAB

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions: hypersensitivity vasculitis, angioedema, and other hypersensitivity reactions requiring hospitalization, have been reported with PRALUENT treatment
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to alirocumab or any excipient in PRALUENT [see Contraindications (4) ]

PITAVASTATIN

5 WARNINGS AND PRECAUTIONS • Myopathy and Rhabdomyolysis: Risk factors include age 65 or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher pitavastatin tablets dosage
Temporarily discontinue pitavastatin tablets in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis
Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the pitavastatin tablets dosage
Rare reports of fatal and non-fatal hepatic failure have occurred

Clinical Trial Data

No head-to-head clinical studies found for ALIROCUMAB vs PITAVASTATIN.

ALIROCUMAB vs PITAVASTATIN: What You Should Know

Key Differences

ALIROCUMAB is a PCSK9 Inhibitor, while PITAVASTATIN belongs to the Other class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. ALIROCUMAB is administered via Subcutaneous, whereas PITAVASTATIN uses Oral. Route of administration can affect onset of action and patient adherence.

Safety Considerations

ALIROCUMAB carries 4 FDA warnings. PITAVASTATIN carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

Atorvastatin vs PITAVASTATIN→ALIROCUMAB vs Atorvastatin→PITAVASTATIN vs Rosuvastatin→ALIROCUMAB vs Rosuvastatin→PITAVASTATIN vs SIMVASTATIN→ALIROCUMAB vs SIMVASTATIN→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

ALIROCUMAB: DailyMed label · FAERS adverse events · ClinicalTrials.gov
PITAVASTATIN: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

ALIROCUMAB vs PITAVASTATIN

Compare ALIROCUMAB (Praluent) and PITAVASTATIN (Pitavastatin Calcium) — clinical data, side effects, and patient experiences.

ALIROCUMAB

Praluent · PCSK9 Inhibitor

How it works

12.1 Mechanism of Action Alirocumab is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein (...

Approved for

1 INDICATIONS AND USAGE PRALUENT ® is indicated: To reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death

myocardial infarction

stroke

myocardial infarction

SubcutaneousTablet

PITAVASTATIN

Pitavastatin Calcium · Other

How it works

12.1 Mechanism of Action Pitavastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonat...

Approved for

See full prescribing information

OralTablet

Quick Comparison

ALIROCUMABPITAVASTATIN

Drug Class

PCSK9 Inhibitor

Other

Route

Subcutaneous

Oral

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ALIROCUMAB

Muscle Pain

>10%

Injection Site Pain

1-10%

Joint Pain

1-10%

Fatigue

1-10%

Limb Pain

1-10%

Diarrhea

1-10%

Headache

1-10%

Cough

0.1-1%

PITAVASTATIN

Muscle Pain

>10%

Diarrhea

1-10%

Fatigue

1-10%

Nausea

1-10%

Headache

1-10%

Joint Pain

1-10%

Dizziness

1-10%

Shortness of Breath

1-10%

FDA Warnings

ALIROCUMAB

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions: hypersensitivity vasculitis, angioedema, and other hypersensitivity reactions requiring hospitalization, have been reported with PRALUENT treatment
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
If signs or symptoms of serious hypersensitivity reactions occur, discontinue treatment with PRALUENT, treat according to the standard of care, and monitor until signs and symptoms resolve
PRALUENT is contraindicated in patients with a history of a serious hypersensitivity reaction to alirocumab or any excipient in PRALUENT [see Contraindications (4) ]

PITAVASTATIN

5 WARNINGS AND PRECAUTIONS • Myopathy and Rhabdomyolysis: Risk factors include age 65 or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher pitavastatin tablets dosage
Temporarily discontinue pitavastatin tablets in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis
Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the pitavastatin tablets dosage
Rare reports of fatal and non-fatal hepatic failure have occurred

Clinical Trial Data

No head-to-head clinical studies found for ALIROCUMAB vs PITAVASTATIN.

ALIROCUMAB vs PITAVASTATIN: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.